Print Page  Close Window


SEC Filings

S-1/A
OREXIGEN THERAPEUTICS, INC. filed this Form S-1/A on 04/09/2007
Entire Document
 
 

     This License Agreement is made and entered into on this 27th day of June, 2003 (hereinafter “Effective Date”) by and between Oregon Health & Science University (hereinafter “OHSU”), having offices at 2525 SW 1st Ave, Portland, Oregon 97201, and Orexigen Therapeutics, Inc. (hereinafter “LICENSEE”), a Delaware corporation having offices at 28202 Cabot Road, Suite 200, Laguna Niguel, CA 92677.
1.   BACKGROUND
 
1.01   In the course of fundamental research programs at OHSU inventions were conceived which relate to:
     1.01.1 [***] (hereinafter: Screening Patent)
     1.01.2 [***] and [***] (hereinafter: Mouse Patent)
     1.01.3 [***] (hereinafter: Therapeutic Patent)
    The intellectual property rights resulting from these inventions and covered under this Agreement may be subject to the conditions set forth in 37 CFR Part 401.
1.02   OHSU is owner of certain right, title and interest in inventions related to the Screening Patent, Mouse Patent, and claims an interest in the Therapeutic Patent, and OHSU desires to license the Screening Patent and Mouse Patent to LICENSEE and assign ownership of the Therapeutic Patent to LICENSEE.
 
1.03   LICENSEE desires to obtain the licenses to and assignment of the patent rights for public use and benefit by using said patent rights,
 
1.04   OHSU desires to grant license and assignment under those rights to LICENSEE to develop and use products and/or processes or sell products for public use and benefit that utilize the inventions.
 
2.   DEFINITIONS
 
2.01   First Commercial Sale” means the initial transfer by or on behalf of LICENSEE or its sublicensee of Licensed Products or Screening Products in exchange for cash or some equivalent to which value can be assigned for the purpose of determining Net Sales.
 
2.02   Government” means the government of the United States of America.
 
***   Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.